Literature DB >> 3829879

Urinary zinc excretion in Crohn's disease.

L Pironi, M Miglioli, G L Cornia, M A Ursitti, M Tolomelli, S Piazzi, L Barbara.   

Abstract

In order to study the reliability of urinary zinc levels as an index of zinc metabolism and status in Crohn's disease, we evaluated plasma and urinary zinc concentrations, urinary 3-methylhistidine excretion, and Crohn's disease activity index (CDAI) in 42 patients affected by Crohn's disease. Plasma zinc correlated directly with albuminemia (P = 0.01) and inversely with CDAI (P = 0.001). Urinary zinc excretion correlated with urinary 3-methylhistidine (P = 0.001) and plasma zinc levels (P = 0.01), and inversely with CDAI (P = 0.05). However, from multiple regression analysis, it was found that zincemia is influenced by CDAI and not by albumin, whereas zincuria is related to urinary 3-methylhistidine and plasma zinc, and not to CDAI. Our conclusion is that, in Crohn's disease, zincuria can be an index of zinc status when used together with measurements of lean body mass and turnover and factors influencing plasma ultrafiltrable zinc fraction.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3829879     DOI: 10.1007/bf01296288

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  19 in total

1.  Metabolism of 3-methylhistidine in man.

Authors:  C L Long; L N Haverberg; V R Young; J M Kinney; H N Munro; J W Geiger
Journal:  Metabolism       Date:  1975-08       Impact factor: 8.694

2.  Metabolism of administered 3-methylhistidine. Lack of muscle transfer ribonucleic acid charging and quantitative excretion as 3-methylhistidine and its N-acetyl derivative.

Authors:  V R Young; S D Alexis; B S Baliga; H N Munro; W Muecke
Journal:  J Biol Chem       Date:  1972-06-10       Impact factor: 5.157

3.  Competition for zinc among serum albumin and amino acids.

Authors:  E L Giroux; R I Henkin
Journal:  Biochim Biophys Acta       Date:  1972-06-26

4.  Binding of zinc to amino acids and serum proteins in vitro.

Authors:  A S Prasad; D Oberleas
Journal:  J Lab Clin Med       Date:  1970-09

5.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

Review 6.  Ntau-methylhistidine (3-methylhistidine) and muscle protein turnover: an overview.

Authors:  V R Young; H N Munro
Journal:  Fed Proc       Date:  1978-07

7.  Relationship between fat-free weight and urinary 3-methythistidine excretion in man.

Authors:  H Lukaski; J Mendez
Journal:  Metabolism       Date:  1980-08       Impact factor: 8.694

8.  Urinary excretion of 3-methylhistidine: an assessment of muscle protein catabolism in adult normal subjects and during malnutrition, sepsis, and skeletal trauma.

Authors:  C L Long; R H Birkhahn; J W Geiger; J E Betts; W R Schiller; W S Blakemore
Journal:  Metabolism       Date:  1981-08       Impact factor: 8.694

9.  Zinc deficiency: a complication of Crohn's disease.

Authors:  C McClain; C Soutor; L Zieve
Journal:  Gastroenterology       Date:  1980-02       Impact factor: 22.682

10.  Clinical experience of zinc supplementation during intravenous nutrition in Crohn's disease: value of serum and urine zinc measurements.

Authors:  A N Main; M J Hall; R I Russell; G S Fell; P R Mills; A Shenkin
Journal:  Gut       Date:  1982-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.